News
ABSI
4.480
+2.28%
0.100
Weekly Report: what happened at ABSI last week (0715-0719)?
Weekly Report · 4d ago
Scotiabank Sticks to Their Buy Rating for AbSci (ABSI)
TipRanks · 07/15 11:45
Weekly Report: what happened at ABSI last week (0708-0712)?
Weekly Report · 07/15 09:13
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
NASDAQ · 07/12 13:33
1 'Strong Buy' Biotech Stock With 132% Upside Potential
Absci Corp (ABSI) is a biotech company that produces protein development technologies. The small-cap biotech is a component of the benchmark Russell 2000 Index. ABSI uses an integrated drug development platform that builds on traditional biological drug discovery with the help of AI. Analysts have a bullish stance on the biotech stock with a consensus price target of $7.
Barchart · 07/11 08:49
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Corning shares jumped 9.4% to $42.05 on Monday. The company increased its second-quarter core sales guidance. Morphic Holding, Inc. Shares gained 75% after Eli Lilly agreed to buy the company for $57 per share in cash. Shares of Corning rose sharply after the Dow Jones index surged around 200 points.
Benzinga · 07/08 14:19
Weekly Report: what happened at ABSI last week (0701-0705)?
Weekly Report · 07/08 09:13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
CNS CNS Pharma (NASDAQ:CNSP) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $381.0 million. Autonomix Medical stock moved upwards by 37.23% during the session.
Benzinga · 07/04 12:06
Morgan Stanley Initiates Coverage of Absci (ABSI) with Overweight Recommendation
NASDAQ · 07/04 06:07
ABSCI ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/03 20:00
BUZZ-U.S. STOCKS ON THE MOVE-Gulf Resources, Constellation Brands, Absci
U.S. Stock indexes edged higher on Wednesday in a holiday-shortened trading session. The Dow Jones Industrial Average was down 0.10% and the S&P 500 was up 0.33%. Gulf Resources, Constellation Brands and Absci were among the biggest losers.
Reuters · 07/03 17:09
BUZZ-U.S. STOCKS ON THE MOVE-Quest Diagnostics, MGM Resorts, Copper miners
U.S. Stock indexes edged higher on Wednesday in a holiday-shortened trading session. The Dow Jones Industrial Average was down 0.13% at 39,281.17. Top three S&P 500 percentage gainers: Tesla, Newmont Corp. Copper miners rise on higher bullion prices. Quest Diagnostics, MGM Resorts, and copper miners rise.
Reuters · 07/03 16:04
Absci Shares Climb After Morgan Stanley Initiates Coverage at $7 Price Target
Dow Jones · 07/03 14:59
Morgan Stanley starts Absci at overweight, cites AI theme
Morgan Stanley starts Absci at overweight, cites AI theme in biotech/drug development. Morgan Stanley sees Absci as an economical way of gaining exposure to the theme of AI in biotech. The company's lead drug candidate, ABS-101, addresses a target for ulcerative colitis and Crohn's disease.
Seeking Alpha · 07/03 14:51
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, First Foundation, Repay Holdings
Wall Street was set to open slightly lower on Wednesday. Dow e-minis were down 0.03% ahead of a holiday-shortened trading session. Constellation Brands, First Foundation, Repay Holdings were among the top stocks on the day. Investors assessed jobs data and the Federal Reserve's June policy meeting minutes.
Reuters · 07/03 13:15
BUZZ-Absci gains after Morgan Stanley starts with 'overweight' rating
Absci Corp rises 7.7% to $3.2 in premarket trading. Morgan Stanley initiates coverage on AI biologics firm with 'overweight' rating and $7 price target. ABSI is using artificial intelligence and machine learning to reduce costs for antibody therapies.
Reuters · 07/03 11:48
ABSCI CORP <ABSI.O>: MORGAN STANLEY INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $7
Reuters · 07/03 11:02
Absci Initiated at Overweight by Morgan Stanley
Dow Jones · 07/03 09:34
Absci Price Target Announced at $7.00/Share by Morgan Stanley
Dow Jones · 07/03 09:34
Morgan Stanley Initiates Coverage On Absci with Overweight Rating, Announces Price Target of $7
Benzinga · 07/03 09:24
More
Webull provides a variety of real-time ABSI stock news. You can receive the latest news about Absci Corp through multiple platforms. This information may help you make smarter investment decisions.
About ABSI
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.